Table 1 Characteristics of 16 consecutive patients who underwent autologous HCT and were grouped by their numbers of inhibitory KIR–HLA receptor–ligand mismatched pairs
Disease | Indication for HCT | Disease status at the time of HCT | No. of CD133+ cells in the graft (× 106 kg−1) | Natural cytotoxicity (%)a | HLA-Bw | HLA-C | KIR mismatch a | Outcome |
|---|---|---|---|---|---|---|---|---|
NB | Stage 4 | VGPR | 7.9 | 32.0 | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
HD | Relapse | PR | 5.5 | 13.1 | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
HD | Relapse | CR | 4.8 | 35.0 | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
HD | Relapse | PR | 5.0 | 16.8 | 6/6 | Asn80/Asn80 | 2DL1, 3DL1 | Alive, NED |
NB | Stage 4 | VGPR | 7.6 | 13.5 | 4/6 | Asn80/Asn80 | 2DL1 | Alive, NED |
NHL | Relapse | PR | 2.1 | ND | 6/6 | Asn80/Lys80 | 3DL1 | Alive, NED |
NHL | Relapse | PR | 2.2 | 31.0 | 6/6 | Asn80/Lys80 | 3DL1 | Alive, NED |
NB | Stage 4 | VGPR | 8.0 | 15.9 | 6/6 | Asn80/Asn80 | 3DL1 | Died of PD |
NHL | Relapse | PR | 5.9 | 15.6 | 4/6 | Lys80/Lys80 | 2DL3 | Died of PD |
PNET | Metastasis | CR | 5.3 | 16.5 | 4/6 | Asn80/Asn80 | 2DL1 | Died of PD |
DSRCT | Metastasis | CR | 5.4 | 18.4 | 4/6 | Asn80/Lys80 | None | Alive, NED |
NHL | Relapse | PR | 2.5 | ND | 4/6 | Asn80/Lys80 | None | Died of PD |
ES | Relapse | PR | 3.8 | 26.8 | 4/6 | Asn80/Lys80 | None | Died of PD |
NB | Stage 4 | VGPR | 7.8 | 17.7 | 4/4 | Asn80/Lys80 | None | Died of PD |
NB | Stage 4 | PR | 6.0 | ND | 6/6 | Asn80/Lys80 | None | Died of PD |
NB | Stage 4 | VGPR | 8.0 | 15.0 | 4/6 | Asn80/Lys80 | None | Died of PD |
